ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.740
+0.110 (6.75%)
At close: Jan 17, 2025, 4:00 PM
1.750
+0.010 (0.57%)
After-hours: Jan 17, 2025, 6:47 PM EST
ALX Oncology Holdings Employees
ALX Oncology Holdings had 72 employees as of December 31, 2023. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$2,099,431
Market Cap
91.77M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72 | 14 | 24.14% |
Dec 31, 2022 | 58 | 15 | 34.88% |
Dec 31, 2021 | 43 | 20 | 86.96% |
Dec 31, 2020 | 23 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ALXO News
- 4 weeks ago - ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 2 months ago - ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 - GlobeNewsWire
- 4 months ago - ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations - Seeking Alpha
- 5 months ago - ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors - GlobeNewsWire
- 6 months ago - ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer - GlobeNewsWire
- 6 months ago - ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - GlobeNewsWire